Monday, August 17, 2026

A new analysis reveals Medicaid managed care organizations are denying prior authorizations at a higher rate than Medicare Advantage plans. The report compares the administrative burdens and access barriers between the two public programs. For practices with a significant Medicaid patient panel, this data signals a higher administrative lift and potential cash-flow impact. Monitor your Medicaid MCO denial rates against this benchmark and prepare your clinical teams for more frequent peer-to-peer reviews.

Multiple private insurers have signaled plans to drop coverage for GLP-1 weight-loss drugs, including Wegovy and Zepbound, starting in 2027. This follows employer trends to control soaring pharmacy benefit costs. For practices managing patients on these therapies, this creates a concrete coverage cliff. Audit your patient roster for GLP-1 prescriptions now. Develop a patient communication plan to discuss alternative treatments or appeal pathways before January 1, 2027, when new plan years take effect.

Wisconsin physicians are raising concerns that the state's impending Medicaid work requirements, set to take effect in the coming months, will create significant administrative overhead and ethical dilemmas. The rules require beneficiaries to document work activities to maintain eligibility, which clinics will likely need to verify. This adds a new non-clinical documentation layer to patient visits. Practices in Wisconsin should track the implementation timeline from the state's Department of Health Services and prepare front-office staff for eligibility verification changes.

State laws imposing conditions on private equity acquisitions of physician groups are linked to a roughly 50% drop in such deals in 2026. States like California and New York have passed bills requiring approval from state attorneys general or mandating continuity of care. This regulatory friction is reshaping the market for practice sales and partnerships. For independent practice owners considering a transaction, the landscape is shifting toward more regulatory scrutiny and potentially lower valuations from financial buyers.